Jan. 5, 2012 New guidelines from the American Academy of Neurology will help physicians better choose seizure drugs for people on HIV/AIDS medication, avoiding deadly drug interactions and preventing critical anti-HIV drugs from becoming less effective, possibly leading to a more virulent strain of the disease.
Michigan State University's Gretchen Birbeck -- who spends several months each year in the sub-Sahara African nation of Zambia researching epilepsy, HIV /AIDS and cerebral malaria -- is the lead author of the medical guideline, which was co-developed with the World Health Organization through the International League Against Epilepsy.
The research is published in Neurology, the medical journal of the academy, and Epilepsia, the medical journal of the league.
According to the World Health Organization, more than 33 million people worldwide were living with HIV in 2009. Seizure disorders are common among people with HIV, with up to 55 percent of patients requiring treatment with anti-epileptic drugs, known as AEDs, said Birbeck, a professor of neurology and ophthalmology in MSU's College of Osteopathic Medicine.
Until now, formal treatment guidelines did not exist for those with HIV/AIDS who were in need of AEDs, which treat everything from epilepsy to mood disorders to other neurological ailments.
When certain seizure drugs are combined with HIV/AIDS drugs known as antiretrovirals, or ARVs, one or more of the combined drugs may become less effective or more toxic. Seizure drugs that decrease HIV/AIDS drug levels -- such as phenytoin, phenobarbital and carbamazepine -- may cause HIV/AIDS drugs to fail.
"Drug interactions between AEDs and ARVs could result in progression to AIDS and/or reduced seizure control," said Birbeck, also a Fellow of the American Academy of Neurology. "Providing guidelines that help physicians select appropriate therapies for their patients with epilepsy and HIV/AIDS will ultimately improve patient outcomes and possibly decrease the public health threat of the development of drug-resistant HIV."
In early 2011, Birbeck was awarded a $245,000 grant from the National Institute of Neurological Disorders and Stroke to conduct a cohort study in Zambia -- where rates of epilepsy and AIDS are both high -- to provide data on possible drug interactions that could make HIV drugs less effective or the disease drug resistant. Because seizure and HIV/AIDS drug choices are limited in developing countries, the risk of drug interactions is higher in those countries.
"Future research should target epilepsy and HIV/AIDS drug combinations where choices are limited, such as in developing countries, to better understand the risks," Birbeck said. "It also is important that patients know exactly which drugs they are taking and provide that information to all prescribing health care providers caring for them."
Other social bookmarking and sharing tools:
- Gretchen L. Birbeck, Jacqueline A. French, Emilio Perucca, David M. Simpson, Henry Fraimow, Jomy M. George, Jason F. Okulicz, David B. Clifford, Houda Hachad and René H. Levy for the Quality Standards subcommittee of the American Academy of Neurology and the ad hoc task force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN. Epilepsia, 4 JAN 2012 DOI: 10.1111/j.1528-1167.2011.03335.x
Note: If no author is given, the source is cited instead.